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Diet is an important factor in gastrointestinal health. A synbiotic food option 
utilizing prebiotic and probiotic ingredients may be beneficial for improving 
gastrointestinal health. To conduct a human subject study of synbiotic ice cream 
containing prebiotic (inulin) and two strains of probiotics (Lactobacillus casei KE99 and 
Bifidobacterium bifidum) to determine its  effectiveness as a carrier for a these 
ingredients and to identify any negative gastrointestinal side effects.  
The study started with baseline data collection including a food frequency, a three 
day food recall, and one stool sample. The study was a 12 week crossover design with 
three weeks consuming placebo or treatment ice cream then a three week washout period. 
After, participants would switch to the other ice cream. Fecal samples were collected to 
examine bacteria level changes. Participants kept a log book during the two treatment 
periods to track gastrointestinal symptoms and record amount of ice cream consumed.  
There was a not a significant difference in amount of ice cream consumed during 
placebo and treatment periods; t(11)= 0.31, p = 0.98. Change in reported flatulence level 
was not statistically significant; t(11)= -0.82, p = 0.43. There was no significant change 
in number of stools per day between treatment and control; t(11)= -2.09, p = 0.06. 
Change in Bristol scale values during placebo and treatment was not statistically 
  
 
 
significant; t(11)= -0.71, p = 0.49.There was not significant difference in the 
Bifidobacterium bifido values during treatment (M=47.13, SD=103.22) and control 
(M=24.11, SD=80.29); t(12)= 1.72, p = 0.11. Synbiotic ice cream could be an effective 
carrier for probiotics and prebiotics. Consumption did not cause an increase in 
gastrointestinal symptoms. The results of the bacteria level change were not significant. 
Further research is needed. 
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LITERATURE REVIEW 
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Gastrointestinal Health 
Gastrointestinal health is a very important part of overall health and can impact 
quality of life. In the United States colon cancer is the third most common cancer, and the 
risk of developing colon cancer is about one in 20, with nearly 50,000 deaths from colon 
cancer in the last year (1, 2). Approximately 22% of the population have chronic 
constipation, 5.6% have irritable bowel syndrome and over 2.2 million Americans have 
been diagnosed with diverticular diseases. As many as one in 10 Americans over the age 
of 40 have diverticulosis (3, 4). The health of the gastrointestinal tract is affected by 
many factors. These include pH, competition for nutrients, host conditions, metabolic 
interactions among bacteria and individual dietary intakes (5). Several of these factors are 
hard to influence with outside treatments that are non-invasive, and it is difficult to 
measure their effect. The main area that can be impacted with simple treatment is dietary 
intake. Two main categories have been reported in research literature and have measured 
the ability they have to improve gastrointestinal health. These are the consumption of 
prebiotic food ingredients, sometimes called functional foods (e.g. fructooligofructoses) 
and probiotic microorganisms such as Lactobacillus and Bifidobacterium). 
Gastrointestinal Tract and the Gut Microbiota 
The human gastrointestinal (GI) tract contains over 1014 microbial cells with more 
than 1,000 different bacterial type (6). At birth, the GI tract is sterile. The GI tract is 
initially colonized by facultative anaerobic bacteria. After these anaerobic bacteria 
remove any trace of oxygen from the environment colonizing bacteria are determined by 
the infant’s food sources. Breastfed infants receive a wide array of microbiota from their 
mothers including strains of Bifidobacterium (7). Once at adulthood most bacteria in the 
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guy are non-sporing anaerobes including Bifidobacterium spp. and Lactobacillus spp. 
These microorganisms through fermentation break down substrates from diet such as 
dietary fibers and endogenous secretions. Bacteria strains have differing metabolic 
activities and fermentation end products which result in them being categorized as either 
beneficial or potentially pathogenic. The benefits from having the good bacteria strains 
are many. These benefits include: preventing GI tract disorders (including irritable bowel 
disease), preventing metabolic syndrome, improving immune response, decreasing 
lactose intolerance, reducing risk of getting antibiotic-associated diarrhea (especially 
when caused by Clostridium difficile), and potentially decreasing risk of colon cancer (6, 
8, 9). The type and diversity of the microbiota in GI tract is also an environmental factor 
in obesity and the imbalance of the microbiota contribute to liver disease (8).  
Probiotics 
 Research related to the gut microbiota has focused mainly on how it can be 
improved through the addition of more of the beneficial bacteria. Supplements or foods 
that contain these microorganisms are called probiotics. Probiotics are defined as live 
microorganisms that confer a health benefit on the host when administered in adequate 
amounts (9-11). Probiotic supplements can be found in a variety of forms including: pill, 
powder, capsule, gummy, and chewable. Probiotics are also found naturally in certain 
foods, or can be added to foods.   
Taking probiotics can improve the immune response in several ways. Certain 
probiotics work by inhibiting adhesion and displacing pathogens for instance, Esherichia 
coli, Staphylococcus aureus, and Clostridium difficile which decreases risk of illness 
(12).  Studies have shown that taking probiotics during antibiotic treatment can be 
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beneficial to maintaining healthy gut microbiome and decreasing the risk of experiencing 
antibiotic-associated diarrhea (13). Probiotics supplements of Lactobacillus casei, 
Lactobacillus reuteri, or Bifidobacterium animalis BB12 can be used when a patient 
already has acute diarrhea to decrease duration of the illness. Probiotics can be used to as 
treatment for someone with irritable bowel disease, ulcerative colitis, Crohn’s disease and 
other GI disorders. Finally, probiotic usage has been linked to a decrease in serum 
cholesterol. Due to the benefits that probiotics have on overall health, consuming 
probiotics is a good choice when trying to improve overall health.  
Research has been done analyzing probiotic supplements and food products for 
bacterial content and label accuracy. The results of these studies showed that many 
products have labels that are inaccurate with respect to the number of bacteria species and 
type of bacteria species. A few examined products did not contain the bacteria species 
listed, and some contained the same strain but were named differently. Some of these 
studies reported supplements that did not contain viable bacteria (14-18). The safety and 
functionality of these products is impacted by the label accuracy and as such it is 
important to correctly identify not only the species but the strain of bacteria used (14).  
Bifidobacterium 
 Bifidobacterium bifidum is a bacterial species of the bifidobacterium genus and is 
one of the most common probiotic bacteria. This helpful bacteria can be found in 
mammals, including humans. It is a gram-positive rod shaped bacteria that is non-motile, 
anaerobic, and non-spore forming. It can be found living in clusters, pairs, or single units. 
The majority of B.bifidum population is found in the colon and lower small intestine, but 
it can also be found in breast milk and in the vagina. B.bifidum as part of the 
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gastrointestinal microflora helps the GI tract function better and reduces the chances of 
acute diarrhea and can help E.coli infections. Increasing the quantity of B.bifidum in the 
body can help boost immune function by decreasing the symptom severity and length of 
time a person is infected with the common cold (10). This bacteria works in the GI tract 
by breaking down both long and short chain simple sugars. Increasing B.bifidum in the GI 
tract can be achieved in a few ways. This bacteria can be transmitted through breast milk 
from the mother to the infant or it can be consumed in probiotic foods and supplements to 
help improve B.bifidum counts within the gut microbiota.  
In vitro studies demonstrated that fermentation and growth rates of bifidobacteria 
increase when short chain oligofructose is the carbon source and that the chain length 
affects the microflora composition and activity (19-22). Numerous human studies have 
been conducted that demonstrate the effect of consumption of bifidobacteria on 
increasing the colonic bifidobactera and subsequent return to baseline within days of 
discontinued consumption of bifidobateria (23-25).  
Lactobacillus 
 Lactobacillus paracasei subspecies paracasei is a heterofermentative lactic acid 
bacteria. Like Bifidobacterium, it is also a gram-positive rod shaped bacteria. This 
bacteria is commonly used in dairy product fermentation as well as probiotic 
supplements. Like Bifidobacterium, it is found in the human GI tract and found in the 
mouth. It is frequently used in commercial probiotic supplements or probiotic food 
products because it survives transit through the gastrointestinal tract well and retains 
functionality and viability well, especially in food products (26). L.Paracasei subs. 
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Paracasei is a beneficial bacteria that is desirable to have as part of the human gut 
microbiota.  
Prebiotics 
Numerous studies have focused on prebiotic ingredients as functional foods and 
how they impart a positive impact on the health of the gastrointestinal tract (9, 27-29). 
Prebiotics are defined as non-digestable food ingredients that positively affect the host by 
selectively stimulating the growth and/or activity of beneficial bacterial species (such as 
Bifidobacterium and Lactobacillus) in the colon, and thus improve host health (30). Non-
digestable fructooligofructoses are prebiotic ingredients that have been shown to have 
positive effect on host health, reducing the risk of gastrointestinal diseases such as 
diverticulosis, diverticulitis and colon cancer (31-34). Consuming prebiotics does come 
with a risk of certain side effects. The side effects from consuming prebiotics can result 
in a higher level of flatulence and possible constipation and/or diarrhea. These side 
effects usually last a short period of time while the body adjusts to the ingredient. Side 
effects can vary depending on the type of prebiotic (27).  
Fructooligofructoses are categorized by their degree of polymerization. 
Fructooligofructoses that have a degree of polymerization from 2-10 are named 
oligofructose (22, 35). Inulin is a generic term that covers all β (1←2) linear molecules 
with a degree of polymerization (DP) varying from 2 to ~60 units (22, 25). Inulin, as a 
type of fructooligofructose, acts as a growth substrate for gut microflora. The bacteria 
that ferment the inulin gain the energy needed to grow and multiply (21, 33, 35). One 
study found that inulin-type fructans with a longer DP have a better prebiotic effect. This 
included inulin having a higher butyrate and propionate production and better stimulation 
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of lactic acid-producing bacteria (such as Lactobacillus and Bifidobacterium) (36). 
Fructooligofructoses are digested by certain types of bacteria including Bifidobacterium 
and Lactobacillus. When Bifidobacteria is the predominant bacteria in the gut, such as 
the case when fructooligofructoses are ingested in the adequate amounts, the number of 
pathogenic bacteria such as E. coli and Clostridia are decreased by competitive inhibition 
(22, 25, 32). 
Bacteria ferment different varieties of fructooligofructoses at different speeds 
(21). This variation is due mainly to the difference in chain lengths as the shorter chain 
lengths can be broken down more quickly and the longer chains require a longer time. 
This variation in speed may also be correlated to location of fermentation, with longer 
chains being broken down in the more distal regions of the colon at a slower rate. These 
longer chains due to the slower rate and more distal location could lead to less side 
effects including less flatulence. A beneficial dose of 20g per day has been shown to be 
effective in producing an increase in bifidobacteria, although considerable individual 
variation existed (33).  
Mixed findings have been reported for the consumption of inulin or oligofructoses 
(33, 37-39). Results depend on the amount and type of fructooligofructose consumed, 
length of time consumed, and wash out periods between treatments. Side effects 
(abdominal pain, distention, flatulence, constipation or diarrhea) were dependent on these 
same factors. Kruse, et al. concluded that long term inulin supplementation was useful 
and can positively change bifidobacteria without major gastrointestinal discomfort (39). 
A project conducted by Dr. Hutkins at University of Nebraska - Lincoln focuses 
on assessing and enhancing stability of prebiotics in foods.  In this project, the focus is on 
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stability of oligosaccharides in food process; specifically heat processing (baking, 
pasteurization and extrusion) (40).   
A study was initiated by Mendlick to determine the effect of fructooligofructoses 
of different chain lengths on gastrointestinal parameters (41, 42). Nineteen healthy 
subjects aged 20-57 years old took part in a ten-week cross-over designed study. Subjects 
consumed either inulin or oligofructose for three weeks followed by a two-week washout 
period between treatments. Stool samples were collected five times (baseline, two 
treatments, two washout) and analyzed for bifidobacteria. Daily records were kept for 
stool frequency, stool consistency and flatulence frequency. Bifidobacteria counts 
(CFU/ml) were higher (trending toward significance) during inulin and oligofructose 
intakes and washout periods than baseline counts. Inulin and oligofructose treatment 
periods had a significant effect on stool consistency (watery/very hard) and flatulence 
frequency, but not stool frequency, when compared to baseline (P<0.05). Further research 
is needed to confirm these results due to small sample size and the need for a longer 
washout period between treatments. 
A recent study was conducted to determine what effect inulin has on pre-diabetics 
with regard to weight management and ectopic fat. It was an 18-week study broken into a 
nine week weight loss phase and nine week weight maintenance phase. Their findings 
showed that the inulin had two effects on diabetes risk. These effects were promoting 
weight loss and reducing intrahepatocellular and intremyocellular lipids in the subjects 
with prediabetes (43). This study illustrates that inulin could be beneficial for more than 
just improving gut microflora.  
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Synbiotics 
Research has been conducted to examine what happens when probiotic bacteria 
and prebiotics are supplemented together. These supplements and foods are categorized 
as synbiotic since the probiotics and prebiotics work together synergistically to improve 
gastrointestinal health (9). A study of similar design to Mendlick’s study was conducted 
to determine the microbiological effects of consuming a synbiotic containing 
Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in capsule form with 
elderly persons (41, 42, 44). The study was a double-blind randomized controlled trial 
with 18 participants and lasted for eight weeks consisting of three phases: a prefeeding 
period (1 week), the feeding period (4 weeks), and a postfeeding/washout period (3 
weeks). During the feeding phase, the synbiotic group received supplements of six g of 
Raftilose Synergy1™ (combination of inulin and oligofructose) and a gelatin capsule 
containing 100 mg of a Freeze-dried probiotic containing ∼3.5 × 1010 CFU each of B. 
bifidum strain BB-02 and B. lactis BL-01 (Rhodia). The placebo group received six g of 
maltooligosaccharides. All capsules were taken with a cold drink two times a day after 
meals. Fecal samples from weeks 1, 3, 4, 5, 6, and 8 were collected and analyzed. 
Throughout the feeding period both bifidobacteria species were detected in fecal samples 
from all subjects in the synbiotic group. Of these, at least one species remained detectable 
in fecal samples three weeks after feeding in subjects that had none of these species 
present during the control week. The results indicated that synbiotic consumption 
increased the size and diversity of protective fecal bifidobacterial populations, which are 
often reduced in older people. This study had a slightly longer washout period than the 
previous, and had positive results.  
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A study using yogurt by Palaria, et al. had a similar design. It was divided into 
five consecutive periods: a pre-feeding period (1 week), a feeding period (3 weeks), a 
washout period (4 weeks), a second feeding period (3 weeks), and a final washout period 
(4 weeks) (45). Fecal samples were collected at the start and at the end of the first week. 
During the first feeding period, the subjects daily consumed either 94 g of placebo, which 
consisted of milk acidified to pH 4.2 with lactic acid, or 94 g of a drinkable yogurt 
containing 109 to 1010 CFU of strain B. animalis subsp. lactis Bb-12 and 1 g of inulin per 
serving. The yogurt was prepared with skim milk and a standard yogurt starter blend 
consisting of Streptococcus thermophilus and Lactobacillus bulgaricus, together with 
the B. animalis subsp. lactis Bb-12 culture and had a final pH of 4.2. Fecal samples were 
collected at the end of each of the three (3) weeks. The subjects consumed neither the 
yogurt nor the placebo during the subsequent washout period. Single fecal samples were 
collected at the end of every two (2) weeks. A live/dead PCR procedure indicated that the 
Bb-12 microorganism was detected in the fecal samples was alive. A significant increase 
(P < 0.001) in the total bifidobacterial numbers was observed in both groups of subjects 
during the final washout period compared to the prefeeding period. This increase in total 
bifidobacteria corresponded with a significant decrease (P < 0.05) in numbers of 
clostridia but not enterobacteria.  
Prebiotic, Probiotic and Synbiotic Ice Cream  
Many studies have been conducted to determine if ice cream would be an 
effective carrier for prebiotics, probiotics, or synbiotics. These studies were conducted 
mostly to determine the palatability or sensory acceptability of these products as well as 
their ability to keep the bacteria viable (41, 46).  
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The Wood and Lum and Albrecht project objective was to determine consumer 
acceptability of ice cream with prebiotic ingredients. A commercial ice cream mix was 
made substituting 0%, 10%, 20%, or 30% of the sugar for either Fructooligosaccharides 
(FOS) or inulin. Participants rated the synbiotic ice cream for its sensory attributes of 
sweetness, smoothness, and vanilla flavor (47, 48). When 10% and 20% inulin ice cream 
were compared to the control (0%), no significant differences in sweetness, smoothness, 
vanilla flavor or overall acceptability were found (P < 0.05). The 30% inulin ice cream 
was significantly less sweet than the control and 10% and 20% inulin ice cream. The 30% 
inulin was less smooth and had less vanilla flavor than the control, and was less 
acceptable than both the control and the 10% inulin ice cream (P < 0.05). For 10% and 
20% FOS ice cream, no significant differences were found in sweetness, smoothness, 
vanilla flavor or overall acceptability compared to the control (P < 0.05). These results 
suggest that FOS and inulin may be acceptable ingredients in ice cream when substituted 
up to 20% of the sugar. 
 A few studies examined the use of just probiotics in ice cream to determine if it 
would be a viable probiotic carrier. The strains used in the first study 
included:  Lactobacillus acidophilus, Bifidobacterium bifidum. Sensory results were 
positive but the bacteria counts decreased throughout the 90-day storage, however did 
maintain their probiotic qualities (49). The second study illustrated that ice cream is not 
good at maintaining the viability of the bacteria. However, if the ice cream is made with a 
prebiotic such as FOS or inulin, these ingredients help to maintain the viability of the 
bacteria (50). In both studies, the ice cream was made by inoculating some of the milk 
and then adding it after cooling down the rest of the ingredients. Cruz and colleagues 
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reviewed the potential for ice cream to be a probiotic food carrier. Two studies with 
probiotics in ice cream reported that the bacteria survived the freezing process (51).  Only 
one study could be found where they actually tested a probiotic ice cream formula in a 
human trial to determine its effects. This study examined the impact of probiotic ice 
cream consumption on levels of Salivary Mutans Streptococci (SMS) during and after the 
trial. They found that the levels of the SMS decreased during treatment, but by six 
months post treatment, the SMS levels were similar to baseline (52). 
Several studies could be found which examined the effectiveness of prebiotics 
and probiotics used together synbiotically. One study examined the differences between 
prebiotic, probiotic and synbiotic ice cream. Their probiotic ice cream contained two 
Lactobacillus species (L. rhamnosus and L. casei). These were used independently within 
fruit or vanilla flavored ice cream. Inulin (2.5%, 5% or 10%) replaced part of the 
stabilizer for the prebiotic ice cream and the synbiotic ice cream used either 3 or 6% 
inulin with either of the probiotic organisms. All ice cream samples were effective at 
maintaining probiotic function (46).  
Two UCARE students (Lim and Mills) examined the sensory characteristics of a 
synbiotic ice cream in which 10 %, 20% or 30% of the sugar was substituted with either 
inulin or fructooligosaccharide (FOS) (53). The probiotic species, Lactobacillus casei 
KE99 (0.3g) and Bifidobacterium bifidum (0.3g), were formulated in the ice cream 
products to make a synbiotic ice cream. Both probiotics used were purchased as freeze 
dried cultures from ProbioFerm in Des Moines, Iowa (54). These probiotics were labeled 
as 100% pure and food grade. Their results reported that the 30% FOS negatively 
affected the flavor and texture. The addition of inulin did not affect the sweetness, 
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smoothness, flavor, texture, and overall acceptability of the ice cream treatments. The 
addition of the probiotics did not affect any of the sensory characteristics of the ice cream 
samples. Another UCARE student (Irby) then examined the viability of the probiotics 
during ice cream storage (55). The results of this study demonstrated that the probiotics, 
Lactobacillus casei KE99 (0.3 grams) and Bifidobacterium bifidum (0.3 grams) continued 
to be viable over a four month period (120 days), making these bacteria a good choice to 
use as a probiotic and the ice cream a good synbiotic carrier. These two strains were the 
same strains chosen for our research study.   
Recent studies examined the effectiveness of using microencapsulation (MEP) to 
determine the effect on bacteria survival within synbiotic ice cream. The results of all the 
studies have reported slower reduction in probiotic bacteria over storage time (56-59). 
The best results were reported when the MEP bacteria was incorporated into chocolate 
particles (57). Overall, all showed MEP to be an effective method for maintaining 
probiotic viability within ice cream. These studies were all published after our study 
design was set and underway. 
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CHAPTER 2 
Problem Statement 
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Based on the literature review and previous research conducted, the objectives of 
our study are to determine if there are any significant gastrointestinal side effects from 
consuming synbiotic ice cream as well as to examine how the bacteria counts change 
prior to eating the ice cream, during consumption, and post consumption. 
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ABSTRACT 
Background: Diet is an important factor in gastrointestinal health. A synbiotic food 
option utilizing prebiotic and probiotic ingredients may be beneficial for improving 
gastrointestinal health.  
Objective: To conduct a human subject study of synbiotic ice cream containing prebiotic 
(inulin) and two strains of probiotics (Lactobacillus casei KE99 and Bifidobacterium 
bifidum) to determine its  effectiveness as a carrier for a these ingredients and to identify 
any negative gastrointestinal side effects.  
Methods: The study started with baseline data collection including a food frequency, a 
three day food recall, and one stool sample. The study was a 12 week crossover design 
with three weeks consuming placebo or treatment ice cream then a three week washout 
period. After, participants would switch to the other ice cream. Fecal samples were 
collected to examine bacteria level changes. Participants kept a log book during the two 
treatment periods to track gastrointestinal symptoms and record amount of ice cream 
consumed.   
Results: There was a not a significant difference in amount of ice cream consumed 
during placebo and treatment periods; t(11)= 0.31, p = 0.98. Change in reported 
flatulence level was not statistically significant; t(11)= -0.82, p = 0.43. There was no 
significant change in number of stools per day between treatment and control; t(11)= -
2.09, p = 0.06. Change in Bristol scale values during placebo and treatment was not 
statistically significant; t(11)= -0.71, p = 0.49.There was not significant difference in the 
Bifidobacterium bifido values during treatment (M=47.13, SD=103.22) and control 
(M=24.11, SD=80.29); t(12)= 1.72, p = 0.11.  
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Conclusion: Synbiotic ice cream could be an effective carrier for probiotics and 
prebiotics. Consumption did not cause an increase in gastrointestinal symptoms. The 
results of the bacteria level change were not significant. Further research is needed. 
 
Key words: probiotic, synbiotic, prebiotic, synbiotic ice cream, Bifidobacterium bifidum, 
Lactobacillus casei KE99  
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INTRODUCTION 
Human gastrointestinal health may be improved by the consumption of prebiotic 
food ingredients and foods containing probiotic microorganisms such Lactobacillus and 
Bifidobacterium (1).  
Prebiotics are defined as “nondigestable food ingredients that have a beneficial 
impact on the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacteria in the colon and thus improving host health” (2, 3). These 
prebiotics are nondigestable because the host, humans, lack the enzymes required to 
break the beta (β) bonds that hold the prebiotic together. These prebiotics reach the colon 
still intact since the host cannot break them down. Certain strains of beneficial bacteria 
found in the gastrointestinal tract, especially Bifidobacterium and Lactobacillus, are able 
to break the β bonds in the prebiotics providing an energy source for the bacteria and as 
well creating byproducts of fermentation that are beneficial to the host.  
Nondigestable fructooligofructoses, including inulin, are prebiotic ingredients that 
have been shown to have positive effects on host health, reducing the risk of 
gastrointestinal diseases such as diverticulosis, diverticulitis, and colon cancer (4-9). 
Inulin is a generic term that covers all β (1←2) linear molecules and their degree of 
polymerization (DP) varies from 2 to ~60 units (10, 11). The inulin then serves as a 
growth substrate for the gut microflora (8, 12, 13).  
Mixed findings have been reported for the consumption of inulin or oligofructoses 
(8, 14-16). Results depend on the amount and type of fructooligofructose, consumed, 
length of time consumed, and wash out periods between treatments. Some subjects have 
experienced side effects from consuming inulin that range from an increased level of 
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flatulence to possible constipation and/or diarrhea (4). Findings show that bacteria 
ferment different chain lengths at different speeds. The differing speeds may be 
correlated to location of fermentation, with the longer chains being broken down in the 
more distal regions at a slower rate. The longer chains at a slower rate could lead to less 
side effects, including less flatulence (17). A beneficial dose of 20g per day has been 
shown to be effective in producing an increase in bifidobacteria, although considerable 
individual variation existed (8). When Bifidobacteria is more predominant in the gut, 
such as the case when inulin and other frutooligofructoses are ingested in the proper 
amounts, the number of pathogenic bacteria such as E. coli and Clostridia are decreased 
by competitive inhibition which can improve GI health (7, 12, 13). 
Numerous human studies have been conducted that demonstrate the consumption 
of bifidobactera increases colonic bifidiobacteria, and when stopped, levels return to 
baseline (10, 18, 19). In vitro studies demonstrated that fermentation and growth rates of 
bifidobacteria increase when short chain oligofructose is the carbon source and that the 
chain length affects the microflora composition and activity (11, 14, 20, 21). According 
to a Health and Human Services report, previous research with probiotics has been very 
inconsistent when describing the intervention, reporting the results of the intervention, 
and providing information regarding genus, species, and strain. Improving these aspects 
in future research was recommended (22). The safety and functionality of these products 
is dependent on labeling accuracy. Unfortunately accurate labelling has not always been 
found (23-25).  Rijkers and colleagues noted that adverse events were not well described 
and the food matrix used for the probiotic was not identified (26).  
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Recently, many studies have investigated the co-administration of prebiotics and 
probiotics called synbiotics. Synbiotics may help enhance the benefits provided by either 
pre- or probiotic supplementation (3, 27, 28). Studies have been conducted to evaluate the 
sensory properties of either probiotic, prebiotic, and synbiotic ice creams (29-31). For 
their probiotic ice cream, two Lactobacillus species (L. rhamnosus and L. casei) were 
used independently with either fruit or vanilla flavors. Inulin (2.5%, 5% or 10%) replaced 
part of the stabilizer for the prebiotic ice cream and the synbiotic ice cream used either 3 
or 6% inulin with either of the probiotic organisms (29). Another study tested the 
palatability of prebiotics replacing 10%, 20%, and 30% of the sweetener with inulin or 
FOS. The 10% was found to be the most tolerated with the 20% being acceptable and the 
30% not accepted. This same prebiotic ice cream was then tested as a synbiotic mixture 
with probiotic species, Lactobacillus casei KE99 (0.3g) and Bifidobacterium bifidum 
(0.3g) added and the same tolerance levels were found (31). Cruz and colleagues 
reviewed the potential for ice cream to be a probiotic food carrier. Two studies with 
probiotics in ice cream showed they survived the freezing process (30). Clinical studies 
have not been conducted with the probiotic, prebiotic or synbiotic ice cream 
formulations.  
The objective to our study was to determine if there are any significant 
gastrointestinal side effects from consuming synbiotic ice cream as well as to examine 
how the bacteria counts change prior to eating the ice cream, during consumption, and 
post consumption. For this study a randomized, blind, crossover, placebo controlled 
human trial of synbiotic ice cream containing the prebiotic inulin and probiotics 
Lactobacillus casei KE99 and Bifidobacterium bifidum was performed to test the 
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effectiveness of ice cream as a carrier for prebiotic and probiotic ingredients and 
examined the impact on gastrointestinal health. 
SUBJECTS AND METHODS 
Study Design 
The study was a 13 week blind, placebo-controlled crossover trial where 
participants were randomly assigned and either consumed synbiotic ice cream or plain 
(placebo) ice cream for a three-week treatment period followed by three-week washout 
period as suggested by the design of other studies and the findings on these particular 
bacteria strains (32-34). The three-weeks of treatment followed by three-weeks of 
washout was then repeated with the opposite ice cream type, either synbiotic or placebo. 
Baseline data was collected the week prior to the start of the first treatment of the 
study. At the start of each week of the three week treatment periods, participants received 
seven one-half cup containers of ice cream, to be consumed daily for the next week. At 
the end of that week, participants brought in their stool sample and received next week’s 
supply of ice cream. In blinded fashion, these portion cups for the treatment and placebo 
were identically packaged  
Ice Cream Formulation  
The ice cream formulation used was the same formulation that had been tested 
previously for sensory qualities and probiotic stability. The bacteria were pure freeze-
dried food grade probiotics (Lactobacillus casei KE99 and Bifidobacterium bifidum) 
purchased from ProbioFerm in Des Moines, IA. In each serving of synbiotic ice cream 
participants were consuming approximately 0.7 g of inulin and 0.017 grams or 1 billion 
(1 x 109) CFU per serving of the probiotic bacteria. All ice cream for the synbiotic 
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treatment as well as the control was made prior to starting a treatment period. The 
synbiotic ice cream was made using the following formulation (Appendix 1):  
Ingredients Control 
Synbiotic 
W/10% inulin 
amounts in grams 
Milk 595 595 
Cream 202 202 
Nonfat Dry 
Milk 50 50 
Corn 
Syrup 
Solids 45 45 
Stabilizer 7 7 
Sugar 100 90 
Inulin 0 10 
B.bifidum 0 0.3 
Lacto casei 0 0.3 
 
To prepare the ice cream: Dry ingredients were mixed in with the wet ingredients 
and the ice cream preparation was heated in a microwave during two separate intervals. 
Inulin is obtained in powder form from the manufacturer SourceNaturals. After four 
minutes, the ice cream preparation was stirred and then put back in the microwave for 
three and a half minutes to solubilize the stabilizer. After heating, the ice cream batch are 
cooled using an ice bath until they reached a temperature below 40°C so that the 
probiotics could be at a temperature in which their viability would not compromised. 
Bifidobacterium bifidum and Lactobacillus casei KE99 were obtained from ProBioFerm 
(Des Moines, IA) in 50 billion colon forming units (CFU) per gram. After adding the 
probiotics the batch can be poured into an ice cream maker and removed once the ice 
cream is done churning. Note: These steps are followed for both recipes minus the 
addition of the probiotics and prebiotics to the control. Once the machine finished the ice 
cream was measured out into half cup servings and stored in individual plastic containers 
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with lids. These were then stored in a standard freezer until they were given to the 
participants.  
Participants 
The study was approved by the Institutional Review Board and all volunteers 
gave written informed consent prior to the start of the project. Participants were recruited 
through posters placed in campus buildings (Appendix 2). Emails were sent out to the 
current and previous class of dietetic interns upon approval of the internship program 
director (Appendix 3). Subjects had to be a student or faculty member of University of 
Nebraska – Lincoln for ease of safety with regard to any potential health concerns. The 
participants filled out a screening tool to determine if they met the requirements to be 
participants (Appendix 4). Potential subjects with a history of colon diseases, 
diverticulosis or diverticulitis, chronic diarrhea or constipation, and recent antibiotics in 
the last six weeks were excluded from the study, as were women who were pregnant or 
breastfeeding. Participants were asked to read through and sign a document of informed 
consent (Appendix 5). All participants were asked to continue following their normal diet 
routine and not modify it in any way, In particular, they were asked not to increase 
probiotic or prebiotic consumption from their usual intake. 
Sampling  
A food frequency, a three-day diet recall, and a stool sample were collected at 
baseline (Appendix 6).  Then participants filled out a daily log book during both 
treatments periods to track stool/flatulence frequency, stool consistency, and percent of 
ice cream consumed as well as providing them with space to log any additional 
comments (Appendix 7). The participants were asked to provide a total of 19 stool 
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samples throughout the study; one at the end of each week, plus one for each of the first 
three days of the washout periods. These were to be collected on days 0, 7, 14, 21, 22, 23, 
24, 28, 35, 42, 49, 56, 63, 64, 65, 66, 70, 77, 84 (Appendix 8). Samples were brought to 
the researcher utilizing the collection tubs that the participants used to collect the 
samples. These samples were held at -20°C until processing.  
Food recall and Food Frequency 
Food recalls were collected and analyzed for each participant to determine a 
baseline of how much fiber they usually consume as well as how many probiotic food 
items they usually consume. The food recalls were analyzed using USDA’s SuperTracker 
to get a consistent and accurate picture of the participants’ usual intake (35) (example 
pages Appendix 9-10). The food frequency was used as a supplemental piece to view 
how much the participants reported that they usually consume of various prebiotic and 
probiotic food sources. The food frequency tool was designed specifically for this study 
but utilized information on high and moderate prebiotic and probiotic food sources.  
Log book  
Participants were given log books to keep track of the following during the two 
treatment periods: ice cream consumed (percentage scale from 0% to 100%), flatulence 
level (Likert scale from 0 to 10), number of stools, and the Bristol scale for stool 
consistency.  
Preparation of cultures 
In preparation for analysis of the fecal samples procedures had to be completed on  
the same pure freeze dried cultures from ProbioFerm (Des Moines, IA) used within the 
ice cream.  The cultures were grown in Difco Lactobacilli MRS Agar and Difco 
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Lactobacilli MRS broth (Becton, Dickinson and Co., Franklin Lakes, NJ) and incubated 
in an airtight container with an GasPak™ EZ Anaeobe Container System with Indicator 
(Becton, Dickinson and Co., Sparks, MD) at 37°C overnight. Growth was checked the 
following day. If there was not enough growth they were left in overnight to continue 
growing.  If growth was seen the sample was removed from the incubator and the next 
steps were taken. Growth on the plate was examined. One or two well isolated colonies 
would be picked with a sterile loop and streaked onto a new MRS agar plate. The 
incubation step was repeated as above followed by streaking of one or two well isolated 
colonies from each plate. This was done a minimum of four times to ensure purity of the 
culture.  
An isolated colony was picked from each plate and stained using a gram stain kit.  
Both B.bifidum and L.casei are gram positive rods found in clusters, pairs, or 
independently. The gram stained cultures were examined under a microscope to 
determine if the cultures were the correct stain color, correct shape, and colony formation 
style. One or two times the slides showed a mix of cocci and rods. The steps of isolation, 
growth, and staining were repeated until specimens under the microscope looked correct. 
Once the gram stain results showed the correct shape, colony formation, and gram stain 
results, isolated colonies were picked with a sterilized loop and placed in Difco 
Lactobacilli MRS broth (Becton, Dickinson and Co., Franklin Lakes, NJ) for a final 
incubation with the same condition as previously described. The next day samples were 
taken out and vortexed briefly to mix. 1 mL of sample was extracted and centrifuged at 
1,700xg for three minutes, supernatant was discarded.  
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DNA was extracted using QuickExtract™ Bacterial DNA Extraction Kit 
(Epicentre, Madison, WI) with the following changes to the protocol: The sample pellet 
from above was used and 500 mL quick extract was added to the tube containing the 
pellet. Sample was Vortexed for 45 seconds, incubated at 65°C for ten minutes, vortexed 
for 30 seconds, then incubated at 95°C for two minutes.  
The bacterial DNA was then amplified using primers 27F and 1492R (barcoded) 
(36). The PCR reactions were performed in 20 µL volumes and contained 0.5 L of Terra 
DNA polymerase (Clontech Laboratories, Mountain view, CA), 10 L reaction buffer, 
250 nL of each primer, and 1l of the extracted nucleic acid template or no-template 
control. The cycling conditions were an initial denaturation of 98C for 2 minutes, 
followed by 35 cycles of 98C for 30 seconds, 52C for 30 seconds, and 68C for 90 
seconds; and a final extension of 68C for 4 minutes. Following amplification, PCR 
products were analyzed on a 1.5% agarose gel to confirm correct product size. 
Once completed the concentration level of each sample was checked. This was 
done using the NanoDrop® ND-1000 Spectrophotometer. Cultures were then diluted with 
PCR grade water to get all samples to desired level of 10-15 ng/µL.  10 µL of sample was 
combined with 2 µL of 518R primer and sent to Eurofins genomics (Eurofins MWG 
Operon LLC., Louisville, KY) for sequencing. Despite the fact that the cultures were 
isolated from samples grown from the pure freeze dried cultures the sequencing results 
either had too many unidentified bases (N) in sequencing to have a clear result or they 
matched better to a different bacteria. Both of these results meant that the sequence was 
not strong enough, either due to lack of base pair information or impurity, to be used to 
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make probes. As a result it was determined that primers for the two bacteria should be 
used.  
Primer Selection 
Several sets of primers were designed using the primer designed software at IDT 
(http://www.idtdna.com/primerquest/home/index) using default parameters, for the 
bacterial strains to determine the one that worked best with our specific cultures. To 
select the best set of primers, the primer pairs were tested against four pure cultures of 
each B.bifidum and L.casei by using PCR and gel electrophoresis to determine which 
would amplify the desired cultures and not the others (36). The PCR reactions were 
performed in 20 µL volumes and contained 0.5 L of Terra DNA polymerase (Clontech 
Laboratories, Mountain view, CA), 10 L reaction buffer, 250 nL of each primer, and 1l 
of the extracted nucleic acid template or no-template control. The cycling conditions 
were an initial denaturation of 98C for 2 minutes, followed by 35 cycles of 98C for 10 
seconds, 52C for 30 seconds, and 68C for 60 seconds; and a final extension of 68C for 
4 minutes. Following amplification, PCR products were analyzed on a 1.5% agarose gel 
to determine what the primers had amplified. Initially, three sets of primers for both 
B.bifidum and L.casei were purchased. The first attempt with all primers and all eight 
samples resulted in one promising primer set for each which showed amplification of the 
matching four samples and no amplification of the other four. These two were run 
through PCR again with the same volume and mixture. The cycling conditions were 
modified so that the middle part of the cycle (previously 52C for 30 seconds) had a 
gradient temperature of 54°C, 56°C, 58°C, 60°C, 62°C. The results were examined on a 
1.5% agarose gel. The results were that the B.bifidum 2 primer set was selected and 
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determined to work best at 60°C annealing temperature (see Appendix 11 for full 
sequence information and Figure 1 for gel image).  Unfortunately, the gel results showed 
that the L.casei primer had amplified all eight samples and not just the four L.casei 
samples illustrating that it was not selective enough to be used (see Figure 1).   
The selected B.bifidum primer and all three L.casei primers were tested again 
using SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA) this 
time since this would be the mix used with the participant samples for quantification of 
the bacteria. The PCR reactions were performed in 15 µL volumes and contained 7.5 L 
SYBR® Green PCR Master Mix, 250 nL of each primer and 4l of the extracted nucleic 
acid template. The cycling conditions were an initial denaturation of 95C for 2 minutes, 
followed by 35 cycles of 95C for 10 seconds, gradient of 54C and 60C for 30 seconds, 
and 68 C for 60 seconds; and a final extension of 68 C for 5 minutes. This gave the 
same results as the before with B.bifidum primer 2 being selected L.casei primers not 
selective enough. Six new sets of L.casei primers were purchased for testing. These were 
tested with all four L.casei pure cultures and one B.bifidum culture and the same SYBR® 
Green PCR in volume and ratios listed above. The cycling conditions were modified to 
include a wider temperature gradient with a gradient temperature set of 54°C, 56°C, 
58°C, 60°C, 62°C. The results from testing with these new L.casei primers still resulted 
in no L.casei primer being selected due to either lack of selectivity and incorrect 
selectivity, meaning it did not amplify this exact strain (see Figure 2). Due to time 
constraints with this project the next steps were completed using just the primers selected 
for B.bifidum. 
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Fecal samples analysis 
With the participant samples, the PowerMag™ Soil DNA Isolation Kit (Mo Bio 
Laboratories, Inc., Carlsbad, CA) was used to extract the DNA from the stool samples 
following the manufacturer’s protocol with the following modifications:  the 2 bead-
beating steps were performed in a TissueLyser (QIAGEN Inc., Valencia, CA) and 
samples were incubated in a 95 °C water bath for 5 min between bead-beading steps.  
After DNA was extracted from the samples, their concentration levels were tested 
using the NanoDrop® ND-1000 Spectrophotometer. Once the concentration was 
identified the epMotion M5073 liquid handler (Eppendorf AG, Hamburg, Germany) was 
used to normalize all samples to 10ng/L. This way all concentration levels were 
equivalent before quantifying the bacteria enabling us to get a more accurate picture of 
the level changes throughout treatment.  
The samples were then processed through quantification Polymerase Chain 
Reaction (qPCR) using the 7900HT Fast Real-Time PCR System in duplicate. All these 
were done using the same SYBR® Green PCR Master Mix volumes and ratios mentioned 
above. The V3 region of the 16S rRNA gene specific to eubacterial communities was 
amplified using universal primers 341F and 518R (barcoded). The cycling conditions 
were an initial denaturation of 98C for 10 minutes, followed by 30 cycles of 95C for 30 
seconds, 52C for 30 seconds, and 72C for 30 seconds; and a dissociation step of 95C 
for 15 seconds, 60C for 15 seconds, and 95C for 15 seconds. Next the samples were 
processed through qPCR with the selected B.bifidum primers.  The cycling conditions 
were an initial denaturation of 98C for 2 minutes, followed by 45 cycles of 95C for 10 
seconds, 60C for 30 seconds, and 68C for 45 seconds; and a dissociation step of 95C 
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for 15 seconds, 60C for 15 seconds, and 95C for 15 seconds. The dissociation curve for 
each of the reactions was examined upon completion and samples with a substandard 
curve were re-done (example of one of the Dissociation curves found Appendix 12). The 
quantified results of the sample sets for the 16s and the Bifidobacteria were averaged for 
each participant. These were then quantified using Δct, ΔΔct and fold change (2^(-ΔΔct)). 
The data from these experiments was analyzed using SPSS using a two tailed t-test to 
compare the changes in Bifidobacteria count between the treatment and control times of 
the study.  
Objective  
The objective of this study was to conduct a clinical feeding study to determine if 
synbiotic ice cream is a viable food carrier for prebiotic (inulin) and probiotic 
(Lactobacillus casei KE99 and Bifidobacterium bifidum) food ingredients and to 
determine if it had any negative gastrointestinal effects on the participants. 
RESULTS and DISCUSSION 
Results 
Demographic 
 Initially, 15 participants started the study. The study ended with 13 participants; 
two males and 11 females or 13% males and 87% females (Figure 3) Participants were 
between 21 and 28 years (Figure 4) The average age was 23 years.  
Food Recall and Food Frequency 
 Prior to the start of the study, participants filled out a food frequency and a food 
recall. The food frequency showed participants consumed an average of 3 probiotic foods 
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per week and 36 prebiotic food per week (Figure 5). The food recall results showed an 
average of 19.5 grams of fiber per day and 0.3 probiotics a day (Figures 6 & 7).  
Log Book 
 Results of the participants log book (Appendix 7) are reported in the table 5. 
There was a not a significant difference in the scores for the percentage (from 0%-100%) 
of amount of ice cream consumed during the placebo period (M=92.76, SD=9.74) and the 
amount of ice cream consumed during the treatment period (M=92.67, SD=9.27); t(11)= 
0.31, p = 0.98. There was not a significant difference in the reported flatulence level 
(likert scale from 0-10) during placebo (M=3.74, SD=1.56) and during treatment 
(M=4.02, SD=1.61) periods; t(11)= -0.82, p = 0.43. There was a not a significant 
difference in the reported number of stools per day during placebo (M=1.43, SD=0.51) 
and during treatment (M=1.69, SD=0.74) periods; t(11)= -2.09, p = 0.06. There was not a 
significant difference in the reported number of stools per day during placebo (M=1.43, 
SD=0.51) and during treatment (M=1.69, SD=0.74) periods; t(11)= -2.09, p = 0.06. There 
was not significant difference in the reported Bristol scale values per day during placebo 
(M=3.18, SD=0.17) and during treatment (M=3.35, SD=0.82) periods; t(11)= -0.71, p = 
0.49. 
Bacterial 
 There was not a significant difference in the Bifidobacterium bifido fold change 
values over the treatment (M=47.13, SD=103.22) and over the control (M=24.11, 
SD=80.29) periods; t(12)= 1.72, p = 0.11 (Table 3.6). 
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Discussion 
After collecting and analyzing all of the samples and materials the treatments 
shows no statistically significant impact on gastrointestinal symptoms of the participants. 
The lab analysis results show no statistically significant change as to effectiveness and 
impact on colonization and viability in the gastrointestinal tract. This lack of statistical 
significance was mostly due to the small sample size.   
Participation 
Two participants did not complete the study. One dropped out in two weeks after 
being placed on antibiotic treatment, thus disqualifying them from continuing with the 
study. Another participant dropped prior to the midpoint of the study due to time 
constraints. No participants discontinued participation due to any complications caused 
by treatment from the study. The remaining thirteen participants completed the study. All 
participants missed at least one sample collection during the study either due to travelling 
or because they were simply unable to provide a sample that day. In total, as seen in fig. 1 
two males and 11 females completed the study that originally comprised thirteen female 
and two male participants.  
Food recall and food frequency 
 The results of the food recall showed that the participants had a wide range of 
normal fiber intake, with seven grams being the lowest and 30 grams being the highest. 
The average fiber intake was 19.5 grams, and the average consumption for probiotics was 
0.3 foods per day. The food frequency result showed that most participants consumed 
prebiotic foods with lowest consumption being one prebiotic food a day and highest 
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being approximately seven per day.  Consumption of probiotics was lower. The highest 
was nine probiotic foods per week and the lowest was zero (table 4).   
Log Book 
The two-tailed t-test results showed no significance for any of the reported data 
(table 5 & 8). This was the desired result. The amount of ice cream consumed during the 
treatment and control was not statistically different and looking at the means show they 
are very close similar during both periods. The paired samples correlations showed that 
the change in flatulence level from control to treatment had a strong correlation (0.71) 
which was statistically significant (0.009). This means that even though the actual level 
of change was not statistically significant, partially due to sample size, there is a 
significant level of correlation between when participants were on the treatment and their 
increase in flatulence level. The same result was shown for number of stools. The paired 
samples correlation showed number of stools and treatment had a close correlation (0.82) 
which was significant (0.001). This means that even though the level of overall change 
was not significant the correlation between the change and the treatment was significant.  
Bacteria results; QPCR 
 The overall statistical analysis for the means during the treatment and control 
periods showed no statistical significance (p = 0.11) but did have a clear difference in 
means (treatment = 47.13; control = 24.11) (table 3.6). The results of plotting each 
individual’s fold change values over the study were not as expected. The expectation was 
to see an increase in B.bifidum count during treatment and a decrease in B.bifidum during 
washout following the treatment while seeing levels mostly near baseline throughout the 
rest of the study. The results instead showed spikes during control periods that should not 
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have been there (table 3.7 parts 1 & 2). Further testing needs to be done to determine 
exact cause of the inconsistencies. Many difficulties arose with respect to getting the lab 
procedures to run according to the study plan. Originally, the study design called for 
making probes specific to the bacteria strains being used.  
Conclusion 
The synbiotic ice cream did not have any negative impacts on the participants 
with regard to gastrointestinal symptoms. The results of the bacteria level change were 
statistically insignificant and further research is needed. 
50 
 
 
 
Literature Cited 
1. Petrof EO. Probiotics and gastrointestinal disease: clinical evidence and basic science 
. Anti-inflammatory & anti-allergy agents in medicinal chemistry. 2009;8(3):260-9. doi: 
10.2174/187152309789151977. 
2. Gibson GR, Wang X. Regulatory Effects of Bifidobacteria on the Growth of Other 
Colonic Bacteria. Journal of Applied Microbiology. 1994;77(4):412-20. doi: 
10.1111/j.1365-2672.1994.tb03443.x. 
3. De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. In: Stahl U, 
Donalies U, Nevoigt E, editors. Food Biotechnology. ; 2008. p. 1-66. 
4. Kolida S, Gibson GR. Prebiotic capacity of inulin-type fructans. Journal of Nutrition. 
2007;137(11):2503S-6S.  
5. Wong JM, Jenkins DJ. Carbohydrate digestibility and metabolic effects. Journal of 
Nutrition. 2007;137(11):2539S-46S.  
6. Gibson GR, McCartney AL. Modification of the Gut Flora by Dietary Means. 
Biochemical Society Transactions. 1998;26(2):222-8. doi: 10.1042/bst0260222. 
7. Gibson GR, Roberfroid MR. Dietary Modulation of the Human Colonic Microbiota: 
Introducing the Concept of Prebiotics. Journal of Nutrition. 1995;125(6):1401-12.  
8. Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on fecal 
microflora, microbial activity, and bowel habit in elderly constipated persons. The 
American journal of clinical nutrition. 1997;65(5):1397-402.  
9. Roberfroid MB. Functional effects of food components and the gastrointestinal system: 
chicory fructooligosaccharides. Nutrition Reviews. 1996;54(11):S38-42.  
10. Niness KR. Inulin and oligofructose: what are they? 
. Journal of Nutrition. 1999;129(7):1402S-6s.  
11. Wang X, Gibson GR. Effects of the In vitro Fermentation of Oligofructose and Inulin 
by Bacterial Growing in the Human Large Intestine. Journal of Applied Microbiology. 
1993;75(4):373-80. doi: 10.1111/j.1365-2672.1993.tb02790.x. 
12. Amann MM, Kullen MJ, Martini MC, Busta FF, Brady LJ. Consumption of 
Exogenous Bifidobacteria does not alter Fecal Bifidobacteria and Breath Hydrogen 
Excretion in Humans. Journal of Nutrition. 1998;128(6):996-1002.  
13. Roberfroid MB. Inulin-type fructans: functional food ingredients. Journal of 
Nutrition. 2007;137(11):2493S-502S.  
51 
 
 
 
14. Huebner J, Wehling RL, Parkhurst A, Hutkins RW. Effect of processing conditions 
on the prebiotic activity of commercial prebiotics. International Dairy Journal. 
2008;18(3):287-93. doi: 10.1016/j.idairyj.2007.08.013. 
15. Menne E, Guggenbuhl N, Roberfroid M. Fn-type Chicory Inulin Hydrolysate had a 
Prebiotic Effect in Humans. Journal of Nutrition. 2000;130(5):1197-9.  
16. Kruse HP, Kleessen B, Blaut M. Effects of inulin on faecal bifidobacteria in human 
subjects. British Journal of Nutrition. 1999;82:375-82.  
17. Perrin S, Fougnies C, Grill JP, Jacobs H, Schneider F. Fermentation of Chicory 
Fructo-Oligofructoses in Mixtures of Different Degrees of Polymerization by Three 
Strains of Bifidobactreria. Canadian Journal of Microbiology. 2002;48(8):759-63. doi: 
10.1139/w02-065. 
18. Bouhnik Y, Flourie B, Andrieux C, Bisetti N, Briet F, Rambaud JC. Effects of 
Bifidobacterium sp Fermented Milk Ingested with or without Inulin Colonic 
Bifidobacteria and Enzymatic Activities in Healthy Humans. European Journal of 
Clinical Nutrition. 1996;50(4):267-73.  
19. Bouhnik Y, Flourie B, D'Agay-Abensour L, Pochart P, Gramet G, Durand M, 
Rambaud JC. Administration of Transgalacto-Oligofructoses Increases Fecal 
Bifidobacteria and Modifies Colonic Fermentation Metabolism in Healthy Humans  
 . Journal of Nutrition. 1997;127(3):444-8.  
20. Gibson GR, Wang X. Bifidogenic Properties of Different Types of Fructo-
Oligofructoses. Food Microbiology. 1994;11(6):491-8. doi: 10.1006/fmic.1994.1055. 
21. Rossi M, Corradini C, Amaretti A, Nicolini M, Pompei A, Zanoni S, Matteuzzi D. 
Fermentation of Fructoologosaccharides and Inulin by Bifidobacteria: a Comparitive 
Study of Pure and Fecal Cultures. Applied and environmental microbiology. 
2005;71(10):6150-458. doi: 10.1128/AEM.71.10.6150-6158.2005. 
22. (AHRQ), Agency for Healthcare Research and Quality. Safety of probiotics to reduce 
risk and prevent or treat disease. AHRQ Publication: USDHHS; 2011 September 10, 
2012. Report No.: 11-E007. 
23. Coeuret V, Gueguen M, Vernoux JP. Numbers and strains of lactobacilli in 
some probiotic products. International journal of food microbiology. 2004;97(2):147-56. 
doi: 10.1016/j.ijfoodmicro.2004.04.015. 
24. Weese JS, Martin H. Assessment of commercial probiotic bacterial contents and label 
accuracy 
. Canadian Veterinary Journal. 2011;52(1):43,-46.  
52 
 
 
 
25. Hamilton-Miller JMT, Shah S. 
Deficiencies in microbiological quality and labelling of probiotic supplements. 
. International journal of food microbiology. 2002;72(1-2):175-6. doi: 10.1016/S0168-
1605(01)00703-6. 
26. Rijkers GT, Bengmark S, Enck P, Haller D, Herz U, Kalliomaki M, Rabot S, et al. 
Guidance for substantiating the evidence for beneficial effects of probiotics: current 
status and recommendations for future research. Journal of Nutrition. 2010;140(3):671S-
6S.  
27. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 
2009;136(1):65-80. doi: 10.1053. 
28. Crittenden R, Laitila A, Forssel P. Adhesion of bifidobacteria to granular starch and 
its implications in probiotic technologies. Applied Environmental Microbiology. 
2001;67(8):3469,-75. doi: 10.1128/AEM.67.8.3469-3475.2001. 
29. Di Criscio T, Fratianni A, Mignogna R, Cinquanta L, Coppola R, Sorrentino E, 
Panfili G. Production of Functional Probiotic, Prebiotic, and Symbiotic Ice Creams. 
Journal of Dairy Science. 2010;93(10):4555-64. doi: 10.3168/jds.2010-3355. 
30. Cruz A, Antunes A, Sousa A, Faria J, Saad S. Ice-cream as a Probiotic Food Carrier. 
Food Research International. 2009;42(9):1233-39. doi: 10.1016/j.foodres.2009.03.020. 
31. Mendlik K. The effects of prebiotics on the bifidobacterial of the human colon 
[dissertation]. University of Nebraska - Lincoln; 2006. 
32. Mendlik K, Albrecht J, Schnepf M. Effects of Fructooligofructoses Chain Length on 
the Bifidobacteria of the Human Colon: A Pilot Study 
. Journal of Food and Nutrition Sciences. 2012;3(12):1615-8. doi: 
10.4236/fns.2012.312211. 
33. Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT. 
Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, 
Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time 
polymerase chain reaction and counting of viable bacteria 
. Clinical Infectious Diseases. 2005;40(1):28-37. doi: 10.1086/426027. 
34. Palaria A, Johnson-Kanda I, O'Sullivan DJ. Effect of a synbiotic yogurt on levels of 
fecal bifidobacteria, clostridia, and enterobacteria 
. Applied and environmental microbiology. 2012;78(4):933-40. doi: 
10.1128/AEM.05848-11. 
35. SuperTracker: My foods. my fitness. my health [homepage on the Internet]. 
SuperTracker Home: USDA [cited March 30, 2016]. Available from: 
https://supertracker.usda.gov/. 
53 
 
 
 
36. Baker GC, Smith JJ, Cowan DA. Review and re-analysis of domain-specific 16S 
primers. Journal of Microbiological Methods. 2003;55(3):541-55. doi: 
10.1016/j.mimet.2003.08.009. 
  
54 
 
 
 
Figure 1 B.bifidum and L.casei gel results  
The results for the gel electrophoresis that allowed us to select the correct temperature for 
the bifidobacterium bifido primer. The first five sample were the primers with b.bifidum 
with a temperature gradient of 54°C, 56°C, 58°C, 60°C, 62°C. The next five samples 
were the primers with Lactobacillus casei with the same temperature. This showed that 
the primers did not amplify the other bacteria strain and resulted in choosing 60°C as the 
annealing temperature. The last 10 samples were the B.bifidum and L.cause samples with 
the L.casei primer in the same order as the first 10. This illustrated that the primer was 
not selective enough. 
 
 
 
Figure 2 L.casei primer test results 
The gel electrophoresis for one of the gradient temperature Lactobacillus casei primers 
test. The red boxed area shows the temperature graident of 54°C, 56°C, 58°C, 60°C, 
62°C of both L.casei primers with bifidobacterium bifido. The first five are with primer 4 
and second five are with primer 5. The brightly illuminated samples following were 4 
different L.casei cultures on the same temperature gradient with primer 4 (blue box). The 
remaining samples were the same 4 L.casei cultures on the same gradient with primer 5 
(green boxes). These results show that the primers either amplified everything or almost 
nothing.  
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Figure 3: Gender of participants 
Participants who completed the study (11 females and 2 males), separated by gender with 
the numbers representing percentage of males and females.  
 
 
 
Figure 4: Age of participants 
Participant’s ages. Showing number of participants of each age with age in years on the 
y-axis and number of participants that age across.  
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Figure 5: Food Frequency results 
Food frequency results for probiotic and prebiotic foods. Showing participants and on far 
right the average on the x-axis. The number of times they were consumed per week is 
represented on the y-axis 
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Figure 6: Diet Recall Fiber intake  
The average results from each participant’s 3-day food recall for daily fiber intake. Each 
value given number 1-13 represents an individual participant’s intake in grams. The final 
value on the far right of the x-axis is the overall participant average 
 
 
 
 
Figure 7: Diet Recall Probiotic Intake 
The average results from each participant’s 3-day food recall for daily fiber intake. Each 
value given number 1-13 represents an individual participant’s intake in grams. The final 
value on the far right of the x-axis is the overall participant average 
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Table 1: Log book t-test results  
A two tailed t-test was conducted with a 95% confidence interval and 11 degrees of freedom. The table shows the averages for 
amount of ice cream consumed, flatulence level, number of stools, and what the Bristol rating for stool consistency was during 
the control and treatment periods of the study as reported in mean and standard deviation. The mean difference between values 
during the control and treatment are reported followed by their confidence interval and t-score. All the p values were not 
significant (p > 0.05).   
 
control treatment       
p value 
(placebo ice 
cream) 
(synbiotic ice 
cream) 
Mean 
Difference 95% CI t score 
Amount consumed  
(0%-100%) 
92.76 ± 9.74 92.67 ± 9.27 .08929 6.29 to 6.47 .031 0.98 
Flatulence 
(0-10 Likert scale)  
0 = none, 10 = constant 
3.74 ± 1.56 4.02 ± 1.61 -.28423 1.05 to 0.48 -.817 0.43 
Number of Stool (0-10) 1.4 ± 0.51 1.69 ± 0.74 -.26084 0.54 to 0.01 -2.087 0.06 
Bristol Rating (0-7)  
0 = hard lumps, 7 = liquid 
3.18 ± 0.58 3.35 ± 0.82 -.17484 0.72 to 0.37 -.707 0.49 
 
 
 
Table 2: B.bifidum qPCR t-test results This was a two tailed t-test conducted with a 95% confidence interval and a degrees 
of freedom of 12. It shows the fold change averages for Bifidobacterium bifidum during the control period of the study and 
during the synbiotic treatment period. The mean difference is the difference between the two means. The p value was not 
statistically significant (p > 0.05) 
 
control treatment       
p value 
(placebo ice 
cream) 
(synbiotic ice 
cream) 
Mean 
Difference 95% CI t score 
B. bifidum  
fold change  
47.13 ± 103.22 24.11 ± 80.29 23.02367 6.12 to 52.16 1.72 0.111 
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Table 3: B.bifidum qPCR values 
The quantified values show the fold change for B.bifidum as calculated with the qPCR 
data for each collection during treatment and washout periods are given. Participants are 
listed vertically, and data for each participant is listed horizontally across the table.   
  treatment washout  
person day 7 day 14 day 21 day 1 day 2 day 3 day 7 day 14 day 21 
1 0.81 1.15 0.17 0.05   0.35 0.48 0.41 0.00 
2 239.11 2.40 1.33 2.71 0.36 5.00 7.42 9.41 3.54 
3 0.14 0.08 0.10 0.02 0.08 0.03     5.56 
4 1.14   0.26   5.36 0.00 1.15 0.00 0.00 
6 474.05 4.01 1.56   0.93 4.15 0.14 0.00 0.76 
7 1.24 0.43 0.22 1.39 0.00 0.01 0.15 0.18 2.74 
8 0.84 0.81 3.17 0.14 0.73 0.79 0.30 0.16 0.00 
9 0.61 3.14 0.53 1.99 0.72 0.44   2.28 1.33 
10 6.07   9.11   1.12 1.24 0.07   19.24 
12 0.48 0.61 1.45 4.59 0.00   0.13 0.00 492.46 
13 0.41 6.96   0.43     1.25 5.95 7.14 
14 4.95 0.02 0.07 0.72       3.41 0.11 
15 102.66 451.54 504.44 74.74 61.96 74.74 23.33 919.91 77.78 
 
  
60 
 
 
 
Table 4: B.bifidum qPCR values 
The quantified values show the fold change for B.bifidum as calculated with the qPCR 
data for each collection during the control and washout periods are given. Participants are 
listed vertically, and data for each participant is listed horizontally across the table.   
  control washout 
person day 7 day 14 day 21 day 1 day 2 day 3 day 7 day 14 day 21 
1 0.43   0.32 0.00 0.12 0.01 1.52 1.02 1.21 
2 1.39   2.09 0.70 1.69 9.48 0.00 3.70 0.47 
3 0.38   2.26 1.62   1.26 0.34 5.87 0.67 
4 0.42 1.10 2.37 0.00 0.01 0.03   3.55 4.50 
6 1.44 3.90   0.00 0.67   0.10 0.19   
7 0.45   0.51       1.54 0.70 1.42 
8 6.89 0.01 3.31 1.97 0.00 0.00 16.77 2.10 0.37 
9 0.65 3.45 0.14 1.88 4.54 0.02 1.14 0.66 0.41 
10 9.36   0.70       28.76 6.70   
12 2.68 0.08   0.12       0.46 0.06 
13 1.79   1.30       1.50 0.78 65.29 
14     1.43 0.11 0.37     3.17 0.17 
15 830.89 0.00 43.00 139.99 9.58 47.62 110.36 726.05 186.92 
 
 
 
Table 5: Log Book correlations 
The table shows the correlation between the change in means during the control and 
treatment periods as well as its significance level for the information reported in the log 
books. 
 
 
Correlation p value 
Amount consumed (0%-100%) 0.443 0.15 
Flatulence(0-10 Likert scale)  
0 = none, 10 = constant 
0.712 0.009 
Number of Stool (0-10) .822 .001 
Bristol Rating (0-7)  
0 = hard lumps, 7 = liquid 
.284 .372 
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Chapter 4 
Implications 
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Limitations 
Participants were allowed to follow their normal diet instead of being put on the 
same diet to limit confounding factors. As all participants followed their own diet pattern, 
this could result in statistical inconsistencies. The smaller amounts of prebiotics and 
probiotics added to the ice cream may have been too small to achieve the desired result. 
Sample size itself was also a limitation as there were just 13 participants. A larger sample 
size would have been preferable to determine statistical significance. Purity of the freeze 
dried bacteria was another limiting factor. Many challenges with the lab analysis were 
related to issues with the purity level of the bacteria cultures. 
When new fresh cultures were isolated from the freeze dried bacteria, their 
sequencing results came back more contaminated than the previous times. The results for 
both Bifidobacterium bifido and Lactobacillus casei came back as matching Pediococcus 
acidilactici. Pediococcus acidilactici is a gram-positive cocci that is anaerobic and 
homofermentative. It is able to grow in a variety of temperatures, pH, and osmotic 
pressure and is able to colonize the digestive tract. This probiotic is also available from 
the company where the probiotics used in this study were purchased. Based on the results 
of the analysis and the difficulty with sequencing the bacteria it seems plausible that the 
samples were contaminated before delivery. As only the bacteria strains used were being 
quantified, if the samples did not contain 100% the bacteria stated on the packaging, the 
probiotic impact could have been lower, limiting our ability to obtain clear results.  
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Further Research 
 Based on the results and new research in publication continued research would be 
more efficacious with cultures that can be proven to be 100% pure. Future studies should 
try using microencapsulated probiotics to help the bacteria survive through the stomach. 
To have a better, the quantity of the probiotics and prebiotics added to the ice cream 
could be increased. A larger sample size would be beneficial in understanding the impact 
of the synbiotic on the participants. Lastly, instead of examining the changing level of the 
strains added, examining, the change in the overall microbiome could provide a clearer 
image of the impact this product has on imparting health benefits on the consumer. 
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Appendix 1. Ice cream formulation and directions followed.  
 
Ice Cream Recipes and directions  
Ingredients Control 
Synbiotic 
W/10% inulin 
amounts in grams 
Milk 595 595 
Cream 202 202 
Nonfat Dry 
Milk 50 50 
Corn Syrup 
Solids 45 45 
Stabilizer 7 7 
Sugar 100 90 
Inulin 0 10 
B.bifidum 0 0.3 
Lacto casei 0 0.3 
 
To prepare the ice cream: 
1. Dry ingredients were mixed in with the wet ingredients and the ice cream 
preparation was heated in a microwave during two separate intervals. Inulin is 
obtained in powder form from the manufacturer SourceNaturals.  
2. After 4 minutes, the ice cream preparation was stirred and then put back in the 
microwave for 3 ½ minutes to solubilize the stabilizer.  
3. After heating, the ice cream batch are cooled using an ice bath until they reached a 
temperature below 40° C so that the probiotics could be at a temperature in which 
their viability would not compromised. Bifidobacterium bifidum and Lactobacillus 
casei KE99 were obtained from ProBioFerm in 50 billion colon forming units (CFU) 
per gram.  
4. After adding the probiotics the batch can be poured into an ice cream maker and 
removed once the ice cream is done churning.  
Note: These steps are followed for both recipes minus the addition of the probiotics and 
prebiotics to the control. 
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Appendix 2. Recruitment poster 
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Appendix 3. Recruitment letter 
 
Recruitment Letter 
 
Hello, my name is Erin McNamara. I am a graduate student working towards my Masters 
degree in Nutrition and Health Promotion. To further the research of my thesis project, I 
would like to solicit your help. I am looking for participants who are willing to participate 
in a 13 week study on the effect of synbiotic ice cream on helpful gut bacteria. The study 
is for a synbiotic ice cream which contains the prebiotic ingredient inulin (fiber) and 
probiotics (helpful bacteria) Lactobacillus casei and Bifidobacterium bifido. There will 
be an initial week where we collect baseline data including 1 stool sample and a 3 day 
diet diary. Then there will be 2, 3-week treatment periods or feeding periods, where you 
will consume either the synbiotic ice cream or plain vanilla ice cream. In each of the 
feeding periods you would consume a ½ cup serving of vanilla ice cream, either the plain 
vanilla or the synbiotic, once a day and keep a brief journal of different aspects of how 
you feel. These treatment periods will each be followed by a 3 week wash out period 
where you follow your normal diet. You will be asked to provide 19 stool samples at 
different stages in the study so we can track the levels of the two helpful bacteria. 
Compensation for your efforts would be given upon completion or termination of 
participation in the study as one lump sum in the form of a Walmart gift card. You will 
be given $25 for participation and an additional $5 per stool sample to total up to $120. 
To help further probiotic and prebiotic nutrition research, I ask for your support and 
participation in this study.  For more information and to participate please use the below 
contact information. 
 
Thank you, 
 Erin McNamara 
University of Nebraska - Lincoln 
Department of Nutrition and Health Sciences 
Lincoln, NE 68583-0806 
Phone: 402-206-1433 
Email: erinmm88@gmail.com 
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Appendix 4. Screening Questionnaire 
 
 
Screening questionnaire 
 
1. Are you over 19 years of age?    Yes No 
2. Are you female      Yes No 
If yes, are you currently pregnant or breastfeeding?   Yes No 
If yes, are you post menopausal?    Yes No 
3. Do you have chronic diarrhea or constipation?   Yes No 
4. Do you have diverticulosis or diverticulitis?   Yes No 
5. Do you currently consume probiotics?    Yes No 
If yes how often?      
6. Do you currently consume prebiotics?    Yes No 
If yes how often?       
7. Are you currently or have recently taken antibiotics? Yes No 
If so when and for how long? 
8. Were you breastfed as an infant?    Yes No Uncertain 
If yes for how long? 
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Appendix 5. Letter of informed consent 
 
                                        
____________________________________________________ 
                                                                                College of Education and Human Sciences 
                   Department of Nutrition and Health Sciences                
Informed Consent Form 
Consent Form for Participation in a Research Study 
 
Title of Research Project: The effect of Synbiotic ice cream on gut bacteria viability in 
the GI tract 
Principal Investigator: Erin McNamara, BS, RD   
email: erinmm88@gmail.com  phone: 402-206-1433 
Faculty Advisor:  Dr. Julie A. Albrecht, PhD, RD  
email: jalbrecht@unl.edu   phone: 402-472-8884  
 
Introduction:  
You are invited to participate in a research study to determine the effect of synbiotic ice 
cream on gut bacteria viability. Synbiotic dietary supplements are made of prebiotics—
fiber--combined with probiotics--helpful bacteria. This consent form will give you the 
information you will need to understand why this study is being done and why you are 
being invited to participate. It will also describe what you will need to do to participate and 
any known risks, inconveniences or discomforts that you may have while participating. You 
are encouraged to think this over. You are also encouraged to ask questions now and at 
any time. If you decide to participate, you will be asked to sign this form and it will be a 
record of your agreement to participate. This process is called ‘informed consent.’ You will 
receive a copy of this form for your records 
 
Purpose of the study:   
The purpose of this study is to determine if regular consumption of ice cream containing 
a synbiotic blend of fiber, inulin, and helpful bacteria--Bifidobacterium bifidum and 
Lactobacillus casei--will increase the levels of these two helpful bacteria in the gut. 
 
Procedures: 
If you agree to participate in this study, you will be asked to do the following: 
 Complete a screening form to see if you qualify for the study. You are invited to 
participate if you are a healthy adult with no history of colon diseases, 
diverticulosis/diverticulitis, no chronic diarrhea or constipation, and have not been on 
antibiotics in the last 6 weeks. If you are a women you must be premenopausal and 
not pregnant or breastfeeding.  
 Prior to starting the study (week 0), you will be asked to fill out a 3 day diet diary on 3 
consecutive days to give us an idea of your normal diet.  
 Weeks 1-3 is the first feeding period, you will consume ½ cup portion of ice cream 
daily. The ice cream will either be plain vanilla, made using the UNL dairy store recipe, 
or this same ice cream with two types of helpful bacteria (like those found in yogurt), 
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Lactobacillus casei and Bifido bacterium bifido, and one prebiotic, inulin (a type of 
fiber) added. Each day you will fill out a brief log book evaluating your stool and gas 
levels as well as tracking how much ice cream you consumed.  
 At the end of each week of the study (days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 
84) you will be asked to provide a stool sample (at least 1 gram is needed). This 
sample will need to be collected by you then either brought directly to campus or kept 
chilled or frozen until it can be dropped off in the provided coolers. By using the 
coolers, you do not have to bring the samples immediately to campus but can bring 
them at a time that works best for you. An email reminder to collect each sample and 
schedule a drop off time will be sent to you or you can email the primary investigator. 
All needed equipment will be provided, including stool sample collectors, gloves, and 
coolers.  
 Weeks 4-6 is the first washout period. You will be asked to follow your normal diet and 
collect stool samples on each day for the first 3 days (days 22, 23, 24) of week 4 as 
well as the above mentioned weekly samples. These samples are needed because 
often the most rapid change in number of the helpful bacteria occurs at this time. 
 Weeks 7-9 is the second feeding period and you will do the same process as 
described for weeks 1-3. 
 Weeks 10-12 is the second washout period. The steps will be the same as week 4-6 
with samples collected on the first 3 days (days 64, 65, 66). 
 Email reminders will be sent throughout the study to remind you to collect stool 
samples, schedule drop off times, and to schedule times for you to pick up your ice 
cream. The meeting points will either be Ruth Leverton Hall room 115 or 312.   
 Not everyone has a bowel movement every day. If there is a day that you cannot 
provide a sample you can still continue your participation in the study. If this becomes 
a frequent issue, you may want to discuss discontinuing participation with the primary 
investigator. Also, be aware that each sample you miss will decrease your 
compensation received at the end of the study. 
 
Benefits: 
There are no direct benefits to participants. They are contributing to furthering scientific 
research which could benefit society through the development of a product that may 
promote gut health improvements.  
 
Risks and/or Discomforts: 
Participants may experience some discomfort due to gas, bloating, constipation, or 
diarrhea as a side effect but this usually goes away in a few days and is the normal 
reaction of the body to increasing fiber intake. If any problems arise you should seek 
medical care at your medical care provider at your own expense.  
 
Confidentiality:  
Any information obtained during this study which could identify you will be kept strictly 
confidential. . Documents linking your name to your assigned numeric code will be 
destroyed after all data has been collected and verified. The other paper data (all those 
with just your numeric code) will be stored in a locked cabinet in LEV 312 and will only 
be seen by the investigators during the study and will be stored for the required 3 years 
All stool samples will be stored in LEV 114 or ASCI C120 using the numerical code you 
will be assigned and disposed of after analysis. The information obtained in this study 
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may be published in scientific journals or presented at scientific meetings but the data 
will be reported as aggregated data.  
 
Compensation: 
You will receive a $25 Walmart gift card for participating in this project and an additional 
$5 gift card amount for each stool sample provided. This compensation will be given as 
a lump sum upon completion or termination of participation in the study.  If all stool 
samples are provided, you will receive a Wal-Mart gift card of $120. This final total will 
decrease by $5 for each stool sample that was not provided. For amounts greater than 
$50, your Social Security Number will need to be provided. A copy of this receipt will be 
kept for our records, and you will be given one copy.  
 
Opportunity to Ask Questions: 
As mentioned in the introduction, you may ask any questions concerning this research 
and have those questions answered before agreeing to participate in or during the study. 
Or you may contact the investigator at the phone number or email above. Please contact 
the University of Nebraska-Lincoln Institutional Review Board at (402) 472-6965 to voice 
concerns about the research or if you have any questions about your rights as a 
research participant. 
 
Freedom to Withdraw: 
Participation in this study is voluntary. You can refuse to participate or withdraw at any 
time without harming your relationship with the researchers or the University of 
Nebraska-Lincoln, or in any other way receive a penalty or loss of benefits to which you 
are otherwise entitled. 
 
Consent, Right to Receive a Copy: 
You are voluntarily making a decision whether or not to participate in this research study. 
Your signature certifies that you have decided to participate having read and understood 
the information presented. You will be given a copy of this consent form to keep. 
 
Signature of Participant: 
 
______________________________________ ___________________________ 
    Signature of Research Participant            Date 
  
Participant’s email: _______________________________________ 
  
 
Signature of Principal Investigators: 
 
_______________________________________________________ 
Erin McNamara, BS, RD     Date 
 
_______________________________________________________ 
Julie A. Albrecht, PhD, RD     Date 
 
110 Ruth Leverton Hall  /  P.O. Box 830806  /  Lincoln, NE  68583-0806 / (402) 472-3716 / Fax (402) 472-1587 
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Appendix 6. Food Frequency Form 
Prebiotic 
less than 1 
a week 
Once a 
week 
2-3x a 
week 
4-6x a 
week 
once a 
day 
2+ a 
day 
How often do you eat any fruit fresh or canned (not counting juice?)             
Fruit juice like orange, apple, grape; fresh, frozen, or canned. (not sodas or 
other drinks?             
Vegetable juice, like tomato juice, V-8, carrot             
Green salad             
Potatoes, any kind, including baked, mashed, or french fried             
Vegetable soup, or stew with vegetables             
Any other vegetables, including green beans, peas, corn, brocooli, or any 
other kind             
Fiber cereals like raisin bran, shredded wheat or Fruit-n-Fiber             
Beans such as baked beans, pinto, kidney, or lentils (not green beans)             
bread such as whole wheat, white whole wheat or rye             
 Probiotics 
less than 1 
a week 
Once a 
week 
2-3x a 
week 
4-6x a 
week 
once a 
day 
2+ a 
day 
Kefir             
Yogurt              
Milk with added live cultures             
Buttermilk             
Smoothies, butter, and sour cream which are labeled "cultured"             
Fermented foods like saurkraut, kimchi, or tempeh             
Miso             
Microalgae ex/spriulina, green algae             
Probiotic supplements (pills, powder, etc.)             
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Appendix 7. Daily log book page 
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Appendix 8. 
 
Weekly schedule for study with fecal collection days highlighted in blue.  
Phase  Day of Study   
Prefeeding             0 
Feeding 
1 2 3 4 5 6 7 
8 9 10 11 12 13 14 
15 16 17 18 19 20 21 
Washout 
22 23 24 25 26 27 28 
29 30 31 32 33 34 35 
36 37 38 39 40 41 42 
Feeding 
43 44 45 46 47 48 49 
50 51 52 53 54 55 56 
57 58 59 60 61 62 63 
Washout 
64 65 66 67 68 69 70 
71 72 73 74 75 76 77 
78 79 80 81 82 83 84 
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Appendix 9. USDA supertracker example section from multi-day report 
 
Nutrients Report  
Your plan is based on a default 2000 Calorie allowance. 
Nutrients Target Average Eaten Status 
Total Calories 2000 Calories 1712 Calories OK 
Protein (g)*** 46 g 79 g OK 
Protein (% Calories)*** 10 - 35% Calories 19% Calories OK 
Carbohydrate (g)*** 130 g 228 g OK 
Carbohydrate (% 
Calories)*** 
45 - 65% Calories 53% Calories OK 
Dietary Fiber 25 g 24 g Under 
Total Sugars No Daily Target or Limit 64 g No Daily Target 
or Limit 
Added Sugars No Daily Target or Limit 15 g No Daily Target 
or Limit 
Total Fat 20 - 35% Calories 30% Calories OK 
Saturated Fat < 10% Calories 7% Calories OK 
Polyunsaturated Fat No Daily Target or Limit 7% Calories No Daily Target 
or Limit 
Monounsaturated Fat No Daily Target or Limit 13% Calories No Daily Target 
or Limit 
Linoleic Acid (g)*** 12 g 12 g OK 
Linoleic Acid (% 
Calories)*** 
5 - 10% Calories 6% Calories OK 
α-Linolenic Acid (% 
Calories)*** 
0.6 - 1.2% Calories 0.3% Calories Under 
α-Linolenic Acid (g)*** 1.1 g 0.6 g Under 
Omega 3 - EPA No Daily Target or Limit 9 mg No Daily Target 
or Limit 
Omega 3 - DHA No Daily Target or Limit 34 mg No Daily Target 
or Limit 
Cholesterol < 300 mg 171 mg OK 
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Appendix 10. example page section from daily SuperTracker 
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Appendix 11 
 
Sequences for primers used: 
Forward: 5’-GAG TGT ACC TTT CGA ATA AGC-3’ 
Reverse: 5’-CCC TTT ACG AAT AAA TC-3’ 
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Appendix 12 dissociation curve results for 16s set 1 example image with boxed part 
being one of the samples that was thrown out for inaccuracy.  
 
 
